7G BioVentures — 2022 Investments
1 investments dated 2022 · listed companies and verified rows first · show all
Mesentech Inc.mesentech.comMar 2022
Mesentech develops prostaglandin prodrugs aimed at musculoskeletal regeneration.
BiotechHealthtechVancouver
David Hyman(Executive Officer)Robert Norman Young(Executive Officer, Director)Jay Mohr(Director)David Dvorak(Director)Jonathan Polak(Executive Officer, Director, Promoter)
BoardSamuel Wu(Director)
Co-investorsBeresford VenturesWUTIF Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.